srb-2 Antibody

What is SRB-2/SCARB2 and why is it significant in biological research?

SRB-2/SCARB2 (Scavenging Receptor B2) is a transmembrane protein that belongs to the scavenger receptor family class B, which plays crucial roles in cellular functions related to lysosomal operations and membrane transportation. Unlike its family member SR-BI (Scavenger receptor class B type I) which primarily regulates cholesterol efflux from peripheral tissues to the liver, SCARB2 serves distinct physiological functions . The protein is expressed in various tissues and has been detected in multiple cancer types, including lung, prostate, endometrial, thyroid, and breast cancers . Its presence across diverse tissue types makes it a significant target for both basic research and potential clinical applications.

The importance of SRB-2/SCARB2 in research stems from its involvement in cellular processes that may contribute to disease pathogenesis, particularly in cancer biology. Antibodies against this receptor enable researchers to investigate its expression patterns, localization, and potential functional roles in normal and pathological states. Understanding the distribution and regulation of SRB-2/SCARB2 can provide insights into cellular mechanisms and potentially identify new therapeutic targets.

What are the primary experimental applications for SRB-2/SCARB2 antibodies?

SRB-2/SCARB2 antibodies have demonstrated utility across multiple experimental platforms, making them versatile tools for researchers. Based on validation studies, these antibodies can be effectively employed in the following applications:

• Western Blotting (WB): For detection and quantification of SRB-2/SCARB2 protein in cell and tissue lysates. The protein typically appears at approximately 80 kDa, although the expected molecular weight is 54 kDa, suggesting potential post-translational modifications .

• Immunohistochemistry (IHC): For visualizing SRB-2/SCARB2 protein distribution in paraffin-embedded tissue sections. This application is particularly valuable for cancer studies, as SRB-2/SCARB2 has been successfully detected in various cancer tissues .

• Immunofluorescence (IF): For subcellular localization studies, enabling researchers to examine the distribution of SRB-2/SCARB2 within cells with high resolution .

• Flow Cytometry: For quantifying SRB-2/SCARB2 expression in cell populations, providing data on expression levels across different cell types or under varying experimental conditions .

• ELISA: For quantitative measurement of SRB-2/SCARB2 in solution, allowing for high-throughput analysis of samples .

The diversity of these applications demonstrates the robustness of SRB-2/SCARB2 antibodies as research tools across different experimental paradigms.

How does SRB-2/SCARB2 differ from other scavenger receptors, particularly SR-BI?

While both SRB-2/SCARB2 and SR-BI belong to the scavenger receptor class B family, they exhibit distinct functional roles and tissue distribution patterns. SR-BI primarily functions in regulating cholesterol metabolism, facilitating the transport of cholesterol from peripheral tissues to the liver . This receptor plays a crucial role in reverse cholesterol transport and high-density lipoprotein (HDL) metabolism.

In contrast, SRB-2/SCARB2 serves primarily as a lysosomal membrane protein involved in membrane transportation and reorganization. Unlike SR-BI, SRB-2/SCARB2 has not been extensively characterized for its role in lipid metabolism but rather for its potential involvement in lysosomal functions and as a receptor for certain viruses.

The structural differences between these receptors are reflected in their molecular weights and expression patterns. While SRB-2/SCARB2 appears at approximately 80 kDa in Western blots (with an expected size of 54 kDa), SR-BI has a different molecular weight profile . Additionally, their tissue distribution differs, with SR-BI being particularly abundant in the liver, while SRB-2/SCARB2 demonstrates expression across a broader range of tissues, including various cancer types.

What sample preparation techniques yield optimal results with SRB-2/SCARB2 antibodies?

Effective sample preparation is critical for achieving reliable results with SRB-2/SCARB2 antibodies across different experimental applications. Based on validated protocols, the following preparation techniques are recommended:

For Western Blotting:

• Cell lysates should be prepared under reducing conditions to properly denature the protein.

• Loading approximately 30 μg of protein per lane provides sufficient signal while minimizing background .

• SDS-PAGE should be performed on 5-20% gradient gels at appropriate voltage (e.g., 70V for stacking gel, 90V for resolving gel) for optimal protein separation .

• Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes ensures efficient protein transfer while preventing overheating .

For Immunohistochemistry and Immunofluorescence:

• Tissue fixation with paraformaldehyde helps preserve protein structure while allowing antibody access.

• Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is crucial for exposing epitopes that may be masked during fixation .

• Blocking with 10% goat serum reduces non-specific binding and improves signal-to-noise ratio .

• For immunofluorescence applications, sections should be counterstained with DAPI to visualize nuclei and provide context for SRB-2/SCARB2 localization .

For Flow Cytometry:

• Cell fixation with 4% paraformaldehyde followed by permeabilization is necessary for intracellular staining of SRB-2/SCARB2 .

• Blocking with 10% normal goat serum reduces non-specific binding .

• Incubation with primary antibody at appropriate concentration (e.g., 1 μg per 10^6 cells) ensures optimal staining .

These preparation techniques have been validated to produce consistent and reproducible results across different experimental contexts.

What are the critical parameters for successful antigen retrieval in SRB-2/SCARB2 immunohistochemistry?

Antigen retrieval is a crucial step in immunohistochemistry that significantly impacts staining quality and specificity. For SRB-2/SCARB2 antibodies, heat-mediated antigen retrieval in EDTA buffer (pH 8.0) has been validated as an effective method . This approach helps break protein cross-links formed during fixation, exposing epitopes for antibody binding.

The critical parameters that influence successful antigen retrieval include:

• Buffer Composition and pH: EDTA buffer at pH 8.0 has been shown to be optimal for SRB-2/SCARB2 antibodies, likely due to the nature of the epitopes recognized by these antibodies .

• Heating Method and Duration: While the specific heating protocol may vary depending on laboratory equipment, maintaining consistent temperature and duration is essential for reproducible results.

• Cooling Period: Allowing sections to cool gradually after heat treatment prevents tissue damage and ensures uniform epitope exposure.

• Post-Retrieval Washing: Thorough washing with appropriate buffers removes excess retrieval solution and prepares the tissue for subsequent blocking steps.

• Tissue Type Considerations: Different tissue types may require slight modifications to the antigen retrieval protocol based on their composition and fixation characteristics.

Implementing these parameters consistently has been shown to yield strong and specific staining of SRB-2/SCARB2 in various tissue types, including lung cancer, prostate cancer, endometrial cancer, thyroid cancer, and breast cancer specimens .

What controls should be incorporated when using SRB-2/SCARB2 antibodies?

Incorporating appropriate controls is essential for validating experimental results and ensuring the specificity and reliability of staining patterns observed with SRB-2/SCARB2 antibodies. The following controls should be considered:

Positive Controls:

• Cell lines with known SRB-2/SCARB2 expression, such as 293T and SH-SY5Y, which have been validated for Western blot applications .

• Tissue samples with confirmed SRB-2/SCARB2 expression, such as lung cancer or breast cancer tissues, which have demonstrated positive staining in previous studies .

Negative Controls:

• Isotype control antibody (e.g., rabbit IgG at equivalent concentration) to assess non-specific binding of antibodies of the same isotype .

• Secondary antibody-only control (omitting primary antibody) to evaluate background staining from the detection system .

• Unlabelled sample without primary or secondary antibody to establish baseline autofluorescence or endogenous peroxidase activity .

Additional Validation Controls:

• RNA interference or knockout validation to confirm antibody specificity through selective reduction of target protein.

• Peptide competition assay to verify epitope-specific binding.

• Multiple antibody validation using different antibodies targeting distinct epitopes of the same protein.

The implementation of these controls provides a comprehensive framework for interpreting staining patterns and distinguishing true signals from potential artifacts, thereby enhancing the reliability and reproducibility of experimental results.

Why does the detected molecular weight of SRB-2/SCARB2 (80 kDa) differ from the expected size (54 kDa)?

The discrepancy between the observed molecular weight (~80 kDa) of SRB-2/SCARB2 in Western blots and its theoretical molecular weight (54 kDa) is a common phenomenon that can be attributed to several biological and technical factors . Understanding these factors is crucial for accurate data interpretation:

Post-translational Modifications (PTMs): SRB-2/SCARB2 likely undergoes extensive glycosylation, which can significantly increase its apparent molecular weight. Glycosylation is a common modification of membrane proteins and can add substantial mass to the protein backbone. Other potential PTMs include phosphorylation, ubiquitination, or SUMOylation, which may further alter the protein's electrophoretic mobility.

Protein Structure and Conformation: Despite denaturing conditions in SDS-PAGE, some proteins may not fully linearize due to stable structural elements or hydrophobic regions, leading to altered migration patterns. SRB-2/SCARB2, as a transmembrane protein, contains hydrophobic domains that may influence its behavior during electrophoresis.

Isoform Expression: Alternative splicing or use of different promoters may result in the expression of larger isoforms of SRB-2/SCARB2 in certain cell types or tissues. The consistently observed 80 kDa band across different cell lines suggests this may represent a predominant isoform in human cells .

Technical Considerations: The composition of the gel (5-20% gradient), running conditions, and protein standards used for molecular weight determination can all influence the apparent size of proteins in Western blot analysis.

To differentiate between these possibilities, researchers could employ additional techniques such as enzymatic deglycosylation assays, mass spectrometry analysis, or expression of recombinant proteins to confirm the nature of the size discrepancy. This information is valuable for ensuring accurate identification and characterization of SRB-2/SCARB2 in experimental systems.

How can researchers optimize SRB-2/SCARB2 antibody applications for cancer research?

SRB-2/SCARB2 antibodies have demonstrated utility in cancer research, with successful detection in multiple cancer types including lung, prostate, endometrial, thyroid, and breast cancers . To optimize these applications for cancer research, researchers should consider the following strategies:

Multiplex Staining Approaches:
Combining SRB-2/SCARB2 antibodies with markers for cell proliferation, apoptosis, or cancer-specific antigens can provide contextual information about its potential role in cancer biology. This approach requires careful selection of compatible antibodies raised in different host species and appropriate detection systems to avoid cross-reactivity.

Quantitative Analysis Methods:
Implementing digital image analysis for IHC or IF staining can provide objective quantification of SRB-2/SCARB2 expression levels across different tumor regions, grades, or subtypes. Similarly, flow cytometry offers quantitative assessment of expression levels in cancer cell populations and can be combined with other cancer markers for multiparametric analysis.

Correlation with Clinical Data:
Analyzing SRB-2/SCARB2 expression in patient samples with known clinical outcomes can reveal potential prognostic or predictive value. This requires careful documentation of patient characteristics, treatment history, and follow-up data.

Functional Studies:
Beyond expression analysis, researchers should consider examining the functional significance of SRB-2/SCARB2 in cancer cells through knockdown or overexpression studies, followed by assessment of proliferation, migration, invasion, or response to therapy.

Tissue Microarray Analysis:
Utilizing tissue microarrays containing multiple patient samples enables high-throughput analysis of SRB-2/SCARB2 expression across different cancer types or subtypes, facilitating the identification of patterns that may have clinical significance.

By implementing these optimization strategies, researchers can maximize the value of SRB-2/SCARB2 antibodies in cancer research, potentially revealing novel insights into its role in cancer biology and identifying new therapeutic opportunities.

What strategies can address common challenges in achieving specific staining with SRB-2/SCARB2 antibodies?

Achieving specific staining with SRB-2/SCARB2 antibodies can present several challenges that researchers should be prepared to address. Based on experimental validation data, the following strategies can help overcome common issues:

Challenge: High Background Staining

• Solution: Optimize blocking conditions by extending blocking time or increasing blocking reagent concentration (e.g., 10% goat serum as validated) .

• Solution: Reduce primary antibody concentration while extending incubation time (e.g., overnight at 4°C) .

• Solution: Implement additional washing steps with increased duration or detergent concentration (e.g., TBS with 0.1% Tween) .

Challenge: Weak or Absent Signal

• Solution: Refine antigen retrieval methods, ensuring complete coverage of sections with EDTA buffer (pH 8.0) .

• Solution: Increase primary antibody concentration (up to 5 μg/mL for IF applications) .

• Solution: Extend primary antibody incubation time (overnight at 4°C as validated) .

• Solution: Utilize signal amplification systems compatible with the detection method.

Challenge: Non-specific Binding

• Solution: Implement isotype control antibodies at equivalent concentrations to the primary antibody .

• Solution: Pre-adsorb the primary antibody with non-specific proteins.

• Solution: Apply additional blocking steps targeting endogenous biotin or peroxidase activity.

• Solution: Filter antibody solutions immediately before use to remove potential aggregates.

Challenge: Inconsistent Staining Across Samples

• Solution: Standardize fixation times and conditions for all samples.

• Solution: Process all samples simultaneously using automated staining platforms when possible.

• Solution: Include positive control tissues in each staining batch to verify protocol effectiveness .

Challenge: Discrepancies Between Applications

• Solution: Validate the antibody independently for each application (WB, IHC, IF, flow cytometry) .

• Solution: Adjust antibody concentration based on the specific requirements of each application (e.g., 0.5 μg/mL for WB, 2 μg/mL for IHC, 5 μg/mL for IF) .

Implementing these strategies systematically can significantly improve the specificity and reliability of SRB-2/SCARB2 antibody staining across different experimental applications.

How should researchers interpret variations in SRB-2/SCARB2 expression across different tissue types?

Interpreting variations in SRB-2/SCARB2 expression across different tissue types requires careful consideration of multiple factors. Based on immunohistochemical analyses, SRB-2/SCARB2 has been detected in various cancer tissues including lung, prostate, endometrial, thyroid, and breast cancers, potentially with different expression patterns or intensities . When interpreting these variations, researchers should consider:

Biological Significance:
Differences in expression levels may reflect tissue-specific functions of SRB-2/SCARB2. Higher expression in certain tissues might indicate greater dependence on lysosomal functions or membrane transportation processes. Correlating expression patterns with tissue-specific biological processes can provide insights into the functional relevance of SRB-2/SCARB2 in different contexts.

Pathological Implications:
Altered expression in disease states compared to normal tissues may suggest involvement in pathogenesis. For instance, upregulation in certain cancer types might indicate a role in tumor progression or response to therapy. Systematic comparison between normal and diseased tissues, as well as between different disease stages, can reveal potential pathological significance.

Technical Considerations:
Variations may sometimes result from technical factors rather than biological differences. These include tissue fixation methods, antigen retrieval efficiency, or section thickness. Standardizing these parameters and including appropriate controls helps distinguish technical artifacts from true biological variation .

Cellular Heterogeneity:
Within a single tissue, different cell types may express varying levels of SRB-2/SCARB2. High-resolution techniques like IF combined with cell type-specific markers can reveal cell-specific expression patterns that may be masked in whole-tissue analyses .

Quantitative Approach:
Implementing quantitative scoring systems (e.g., H-score, Allred score) enables objective comparison across tissues. Digital image analysis can further enhance quantitative assessment by providing continuous measurements of staining intensity and distribution.

By considering these factors comprehensively, researchers can derive meaningful interpretations of SRB-2/SCARB2 expression variations that contribute to understanding its biological and potential clinical significance.

What quantification methods are most appropriate for SRB-2/SCARB2 expression analysis?

Selecting appropriate quantification methods for SRB-2/SCARB2 expression analysis depends on the experimental application and research objectives. Based on validated applications, the following quantification approaches are recommended:

For Western Blot Analysis:

• Densitometric analysis using image analysis software to quantify band intensity.

• Normalization to housekeeping proteins (e.g., GAPDH, β-actin) to account for loading variations.

• Inclusion of a concentration gradient of recombinant protein or standardized cell lysate on each blot to create a standard curve.

• Calculating relative expression levels across different samples for comparative analysis .

For Immunohistochemistry:

• Semiquantitative scoring systems such as H-score (combining intensity and percentage of positive cells) or Allred score.

• Digital pathology approaches using automated image analysis software to quantify staining intensity and distribution objectively.

• Tissue microarray analysis for high-throughput quantification across multiple samples.

• Spatial analysis to assess expression patterns in relation to tissue architecture or tumor microenvironment .

For Immunofluorescence:

• Fluorescence intensity measurement at the single-cell level using confocal microscopy and image analysis software.

• Colocalization analysis with subcellular markers to quantify compartmental distribution.

• Ratio imaging to normalize against potential variations in cell thickness or accessibility .

For Flow Cytometry:

• Mean or median fluorescence intensity (MFI) measurements to quantify expression levels per cell.

• Population analysis to determine the percentage of positive cells and expression distribution.

• Multi-parameter analysis to correlate SRB-2/SCARB2 expression with other cellular markers .

For ELISA:

• Standard curve-based quantification using purified protein standards.

• Absolute concentration determination in solution-based samples.

• Comparative analysis across multiple samples under standardized conditions .

How can researchers validate the specificity of their SRB-2/SCARB2 antibody for experimental applications?

Validating antibody specificity is crucial for ensuring reliable experimental results. For SRB-2/SCARB2 antibodies, a comprehensive validation strategy should include multiple complementary approaches:

Genetic Manipulation-Based Validation:

• Knockdown validation using siRNA or shRNA targeting SRB-2/SCARB2, followed by Western blot or immunostaining to confirm reduced signal intensity.

• Overexpression studies with tagged SRB-2/SCARB2 constructs to verify antibody detection of the overexpressed protein.

• CRISPR/Cas9-mediated knockout models as the gold standard for specificity validation, demonstrating complete loss of signal in knockout samples.

Biochemical Validation:

• Peptide competition assays where pre-incubation of the antibody with the immunizing peptide should abolish or significantly reduce specific staining.

• Immunoprecipitation followed by mass spectrometry to confirm that the antibody pulls down SRB-2/SCARB2 rather than cross-reactive proteins.

• Comparative analysis with multiple antibodies targeting different epitopes of SRB-2/SCARB2, which should yield consistent results in terms of molecular weight and cellular localization.

Application-Specific Validation:

• For Western blotting: Verification that the observed molecular weight (approximately 80 kDa) is consistent across different cell types despite the expected size of 54 kDa, indicating a consistent pattern of post-translational modification .

• For IHC/IF: Confirmation of expected subcellular localization patterns and comparison with known expression patterns in positive control tissues .

• For flow cytometry: Comparison of staining patterns between positive cell lines (e.g., U87) and negative controls, including isotype control antibodies and unstained samples .

Cross-Application Consistency:

• Verification that the antibody detects the same protein across different applications (WB, IHC, IF, flow cytometry), acknowledging that sensitivity and optimal conditions may vary between applications .

• Correlation of protein expression data across different detection methods to ensure consistent findings.

Literature Concordance:

• Comparison of results with published data on SRB-2/SCARB2 expression and localization patterns.

• Evaluation of whether the observed staining patterns align with known biology of SRB-2/SCARB2.

Implementing this multi-faceted validation approach ensures that experimental findings accurately reflect SRB-2/SCARB2 biology rather than artifacts arising from antibody cross-reactivity or non-specific binding.

How might SRB-2/SCARB2 antibodies contribute to viral research beyond SARS-CoV-2 studies?

While the search results focus primarily on SARS-CoV-2 RBD antibodies and SRB-2/SCARB2 detection, it's important to consider the broader potential of SRB-2/SCARB2 antibodies in viral research. Scavenger receptors, including those in the class B family, have been implicated in various host-pathogen interactions that extend beyond coronaviruses.

SCARB2 has been identified as a receptor for several enteroviruses, including Enterovirus 71 (EV71) and Coxsackievirus A16, which are major causative agents of hand, foot, and mouth disease. In this context, SRB-2/SCARB2 antibodies could be valuable tools for:

• Studying viral entry mechanisms by blocking receptor-virus interactions or visualizing these interactions through microscopy techniques.

• Investigating tissue tropism of viruses by correlating viral susceptibility with SRB-2/SCARB2 expression patterns across different tissues.

• Developing antiviral strategies targeting host factors rather than viral proteins, potentially offering broader spectrum activity against multiple viral pathogens.

• Examining how viruses might modulate receptor expression levels as part of their pathogenic strategies, which could be assessed through quantitative analysis of SRB-2/SCARB2 in infected versus uninfected cells.

• Understanding potential cross-reactivity between antibodies generated against different scavenger receptors, which might have implications for cross-protection against diverse viral infections.

The technical applications demonstrated for SRB-2/SCARB2 antibodies, including Western blotting, immunohistochemistry, immunofluorescence, and flow cytometry, provide a robust toolkit for addressing these research questions . By applying these methods in viral research contexts, investigators could gain valuable insights into host-pathogen interactions and potential therapeutic targets.

What role might SRB-2/SCARB2 play in understanding cross-reactive antibody responses?

The concept of cross-reactive antibodies has gained significant attention in the context of SARS-CoV-2 research, with studies demonstrating that pre-existing antibodies from exposure to seasonal coronaviruses or other pathogens may recognize SARS-CoV-2 antigens . This phenomenon raises interesting questions about the potential role of scavenger receptors like SRB-2/SCARB2 in cross-reactive immune responses.

Cross-reactive antibodies against SARS-CoV-2 receptor-binding domain (RBD) have been detected in pre-pandemic samples, suggesting their development through prior exposure to related antigens . Notably, these antibodies can exhibit dual functionality—some demonstrate neutralizing activity against SARS-CoV-2, while others paradoxically enhance viral infection . This phenomenon bears conceptual similarity to antibody-dependent enhancement (ADE) observed in other viral infections.

In this context, investigating SRB-2/SCARB2 could provide several insights:

• SRB-2/SCARB2 might function as a receptor for certain viruses or participate in immune complex processing, potentially influencing how cross-reactive antibodies modulate viral entry or immune responses.

• The expression patterns of SRB-2/SCARB2 across different tissues could help explain tissue-specific effects of cross-reactive antibodies, particularly if these receptors participate in antibody-mediated viral entry mechanisms.

• Age-related changes in SRB-2/SCARB2 expression might contribute to the observed differences in cross-reactive antibody responses between elderly and younger populations, as noted in studies of pre-pandemic samples .

• Structural similarities between SRB-2/SCARB2 and viral proteins could potentially explain the development of cross-reactive antibodies that recognize both host and viral antigens.

Methodologically, SRB-2/SCARB2 antibodies could be employed to:

• Assess changes in receptor expression following exposure to viruses or immune complexes

• Investigate potential colocalization of viral particles with SRB-2/SCARB2 in the presence of cross-reactive antibodies

• Block receptor function to determine its role in antibody-mediated enhancement of infection

These approaches could contribute to our understanding of the complex interplay between pre-existing immunity, cross-reactive antibodies, and viral pathogenesis.

How does the trade-off between antibody potency and breadth relate to SRB-2/SCARB2 research?

The concept of a trade-off between antibody potency and breadth is well-documented in viral research, particularly for SARS-CoV-2 antibodies targeting the receptor-binding domain (RBD) . This phenomenon has potential parallels and implications for SRB-2/SCARB2 research, particularly when considering antibodies targeting this receptor and its interactions with various ligands or pathogens.

In SARS-CoV-2 research, antibodies targeting the ACE2 receptor-binding motif (RBM) typically demonstrate high neutralization potency but limited breadth across sarbecoviruses and vulnerability to escape mutations . Conversely, antibodies targeting more conserved epitopes often show broader cross-reactivity but may have reduced neutralization potency against specific variants .

When applied to SRB-2/SCARB2 research, similar principles may be relevant:

• Epitope Targeting: Antibodies targeting highly conserved regions of SRB-2/SCARB2 might recognize the receptor across different species or related family members (like SR-BI), providing broader research applications but potentially with lower specificity for particular functions.

• Functional Domains: Antibodies specifically targeting functional domains of SRB-2/SCARB2 involved in ligand binding or viral interactions might more potently block specific functions but may be less effective against structural variants or related receptors.

• Experimental Approach: Researchers must consider this potential trade-off when selecting antibodies for specific applications. For instance, studies focusing on specific SRB-2/SCARB2 functions might benefit from highly specific antibodies targeting functional domains, while evolutionary or comparative studies might require antibodies recognizing conserved epitopes.

• Therapeutic Development: Understanding this trade-off has implications for developing therapeutic antibodies targeting SRB-2/SCARB2 in disease contexts, where the balance between specificity and breadth must be carefully considered.

The validated applications of current SRB-2/SCARB2 antibodies, including their performance in Western blotting, immunohistochemistry across different cancer types, immunofluorescence, and flow cytometry, suggest they recognize epitopes that are sufficiently conserved to be detected across multiple contexts while maintaining specificity for SRB-2/SCARB2 . This balance between specificity and breadth makes them valuable research tools while highlighting the importance of understanding the potential trade-offs in antibody characteristics for specific research applications.